PURPOSE: To determine the indication and outcomes for Gamma Knife stereotactic radiosurgery (GKSRS) in the care of patients with intracranial sarcomatous metastases. METHODS AND MATERIALS: Data from 21 patients who underwent radiosurgery for 60 sarcomatous intracranial metastases (54 parenchymal and 6 dural-based) were studied. Nine patients had radiosurgery for solitary tumors and 12 for multiple tumors. The primary pathology was metastatic leiomyosarcoma (4 patients), osteosarcoma (3 patients), soft-tissue sarcoma (5 patients), chondrosarcoma (2 patients), alveolar soft part sarcoma (2 patients), and rhabdomyosarcoma, Ewing's sarcoma, liposarcoma, neurofibrosarcoma, and synovial sarcoma (1 patient each). Twenty patients received multimodality management for their primary tumor, and 1 patient had no evidence of systemic disease. The mean tumor volume was 6.2 cm(3) (range, 0.07-40.9 cm(3)), and a median margin dose of 16 Gy was administered. Three patients had progressive intracranial disease despite fractionated whole-brain radiotherapy before SRS. RESULTS: A local tumor control rate of 88% was achieved (including patients receiving boost, up-front, and salvage SRS). New remote brain metastases developed in 7 patients (33%). The median survival after diagnosis of intracranial metastasis was 16 months, and the 1-year survival rate was 61%. CONCLUSIONS: Gamma Knife radiosurgery was a well-tolerated and initially effective therapy in the management of patients with sarcomatous intracranial metastases. However, many patients, including those who also received fractionated whole-brain radiotherapy, developed progressive new brain disease. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: To determine the indication and outcomes for Gamma Knife stereotactic radiosurgery (GKSRS) in the care of patients with intracranial sarcomatous metastases. METHODS AND MATERIALS: Data from 21 patients who underwent radiosurgery for 60 sarcomatous intracranial metastases (54 parenchymal and 6 dural-based) were studied. Nine patients had radiosurgery for solitary tumors and 12 for multiple tumors. The primary pathology was metastatic leiomyosarcoma (4 patients), osteosarcoma (3 patients), soft-tissue sarcoma (5 patients), chondrosarcoma (2 patients), alveolar soft part sarcoma (2 patients), and rhabdomyosarcoma, Ewing's sarcoma, liposarcoma, neurofibrosarcoma, and synovial sarcoma (1 patient each). Twenty patients received multimodality management for their primary tumor, and 1 patient had no evidence of systemic disease. The mean tumor volume was 6.2 cm(3) (range, 0.07-40.9 cm(3)), and a median margin dose of 16 Gy was administered. Three patients had progressive intracranial disease despite fractionated whole-brain radiotherapy before SRS. RESULTS: A local tumor control rate of 88% was achieved (including patients receiving boost, up-front, and salvage SRS). New remote brain metastases developed in 7 patients (33%). The median survival after diagnosis of intracranial metastasis was 16 months, and the 1-year survival rate was 61%. CONCLUSIONS: Gamma Knife radiosurgery was a well-tolerated and initially effective therapy in the management of patients with sarcomatous intracranial metastases. However, many patients, including those who also received fractionated whole-brain radiotherapy, developed progressive new brain disease. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Brian De; Michael D Kinnaman; Leonard H Wexler; Kim Kramer; Suzanne L Wolden Journal: Pediatr Blood Cancer Date: 2017-07-11 Impact factor: 3.167
Authors: Jordan B Fenlon; Mohamed H Khattab; Donna C Ferguson; Guozhen Luo; Vicki L Keedy; Lola B Chambless; Austin N Kirschner Journal: World Neurosurg Date: 2018-12-07 Impact factor: 2.104
Authors: Andrew Yaeh; Tavish Nanda; Ashish Jani; Tzlil Rozenblat; Yasir Qureshi; Shumaila Saad; Jeraldine Lesser; Andrew B Lassman; Steven R Isaacson; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann; Tony J C Wang Journal: J Neurooncol Date: 2015-08-02 Impact factor: 4.130
Authors: V M Willeke; M P Anderson; A Mahadevan; R Rojas; R Bhadelia; A J Thomas; E M Kasper Journal: J Neurooncol Date: 2020-03-05 Impact factor: 4.130